Printer Friendly

BAYER TO MARKET SYNTRO VACCINE IN EUROPE

 BAYER TO MARKET SYNTRO VACCINE IN EUROPE
 KANSAS CITY, Mo., July 30 /PRNewswire/ -- Syntro Corporation


(NASDAQ-NMS: SYNT) today announced that Bayer AG will market and distribute Syntro's PRV/Marker Gold(R) genetically designed vaccines in Europe, following necessary regulatory approvals. Under terms of the agreement, the vaccines will be supplied by SyntroVet Incorporated, a wholly owned subsidiary of Syntro.
 PRV/Marker Gold vaccines prevent pseudorabies, a serious infectious disease of swine caused by a herpesvirus. Known also as "Aujeszky's Disease," pseudorabies causes major economic losses to the swine industry and is the target of eradication efforts in both the United States and Europe.
 Eradication programs require vaccines that effectively stop the spread of infection while allowing the detection of disease carriers by the use of special antibody tests. PRV/Marker Gold was genetically designed by Syntro scientists to meet these criteria, and has captured a major share of the pseudorabies vaccine market in the United States.
 Headquartered in Germany, Bayer AG is an international, broadly diversified chemical and health care company with operations in some 150 countries. The company holds a leading position in the animal health market in Germany and is among the market leaders in most other important animal health markets. In 1991, Bayer reported group sales of approximately 42 billion DM ($28 billion).
 Syntro Corporation is a Kansas City and San Diego-based biotechnology company engaged in the development and commercialization of genetically engineered vaccines for the animal health market. SyntroVet Incorporated manufactures and markets products resulting from Syntro's research programs.
 -0- 7/30/92 R P
 /CONTACT: Jack Falker of Swenson Falker Eilertsen, 612-371-0000, for Syntro, or Dr. J. Donald Todd of Syntro, 913-888-8876/
 (SYNT) CO: Syntro Corporation ST: Missouri IN: MTC SU:


AL -- MN004 -- 5331 07/30/92 17:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 30, 1992
Words:295
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, THURSDAY, JULY 30 /PRN/
Next Article:DELPHI FINANCIAL GROUP REPORTS SECOND QUARTER EARNINGS; SIX MONTHS RECORD RESULTS
Topics:


Related Articles
WENNINGER NAMED CHAIRMAN OF BAYER CORPORATION
Bayer Purchases Animal Health Biological Assets from Pharmacia & Upjohn
Genome Therapeutics Signs Bayer AG as Subscriber to Its Proprietary Microbial Genomics Database
Scios and Bayer Granted Early Termination of Hart-Scott-Rodino Waiting Period by F.T.C. for Natrecor Agreement
Wyeth-Ayerst Laboratories Announces Limited Recall of Tubex(R) Epinephrine Used in Allergic Reaction Kits.
Vaccine shot in arm for Shire.
Bayer's Viral Inactivation Processes Safeguard Against Transmission of Monkeypox Virus.
U.S. acquisitions give European vaccine maker a shot in the arm.
Wyeth Pharmaceuticals Announces Organizational Change.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters